182 related articles for article (PubMed ID: 26212373)
1. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
Lee YC; Michael M; Zalcberg JR
Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer.
Sastre J; Argilés G; Benavides M; Feliú J; García-Alfonso P; García-Carbonero R; Grávalos C; Guillén-Ponce C; Martínez-Villacampa M; Pericay C
Clin Transl Oncol; 2014 Nov; 16(11):942-53. PubMed ID: 25223744
[TBL] [Abstract][Full Text] [Related]
3. Molecular insight of regorafenib treatment for colorectal cancer.
Arai H; Battaglin F; Wang J; Lo JH; Soni S; Zhang W; Lenz HJ
Cancer Treat Rev; 2019 Dec; 81():101912. PubMed ID: 31715423
[TBL] [Abstract][Full Text] [Related]
4. Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer.
Patell K; Mears VL; Storandt MH; Mahipal A
Expert Opin Drug Metab Toxicol; 2024 Apr; 20(4):197-205. PubMed ID: 38497279
[TBL] [Abstract][Full Text] [Related]
5. FMS-like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer.
Hasegawa H; Taniguchi H; Nakamura Y; Kato T; Fujii S; Ebi H; Shiozawa M; Yuki S; Masuishi T; Kato K; Izawa N; Moriwaki T; Oki E; Kagawa Y; Denda T; Nishina T; Tsuji A; Hara H; Esaki T; Nishida T; Kawakami H; Sakamoto Y; Miki I; Okamoto W; Yamazaki K; Yoshino T
Cancer Sci; 2021 Jan; 112(1):314-322. PubMed ID: 33075166
[TBL] [Abstract][Full Text] [Related]
6. Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.
Spiliopoulou P; Arkenau HT
World J Gastroenterol; 2014 Aug; 20(30):10288-95. PubMed ID: 25132745
[TBL] [Abstract][Full Text] [Related]
7. Metastatic colorectal cancer- third line therapy and beyond.
Foo T; Roy A; Karapetis C; Townsend A; Price T
Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
Hanna DL; Lenz HJ
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
[TBL] [Abstract][Full Text] [Related]
9. Multikinase inhibitors modulate non-constitutive proteasome expression in colorectal cancer cells.
Burov A; Grigorieva E; Lebedev T; Vedernikova V; Popenko V; Astakhova T; Leonova O; Spirin P; Prassolov V; Karpov V; Morozov A
Front Mol Biosci; 2024; 11():1351641. PubMed ID: 38774235
[No Abstract] [Full Text] [Related]
10. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib.
Yan Y; Grothey A
Onco Targets Ther; 2015; 8():2949-57. PubMed ID: 26508880
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing to overcome resistance to various therapies for colorectal cancer.
Fong W; To KKW
Cell Mol Life Sci; 2019 Sep; 76(17):3383-3406. PubMed ID: 31087119
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies.
Riechelmann R; Grothey A
Ther Adv Med Oncol; 2017 Feb; 9(2):106-126. PubMed ID: 28203302
[TBL] [Abstract][Full Text] [Related]
13. Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice.
Goel G; Sun W
J Hematol Oncol; 2015 Jul; 8():92. PubMed ID: 26215324
[TBL] [Abstract][Full Text] [Related]
14. S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
Iwasa S; Nagashima K; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Yasui H; Kato K; Okita NT; Shimada Y; Yamada Y
Cancer Chemother Pharmacol; 2015 Sep; 76(3):605-14. PubMed ID: 26220845
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapies for metastatic colorectal cancer].
Kito Y; Yamazaki K
Nihon Rinsho; 2015 Aug; 73(8):1384-90. PubMed ID: 26281694
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
17. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.
Pander J; van Huis-Tanja L; Böhringer S; van der Straaten T; Gelderblom H; Punt C; Guchelaar HJ
PLoS One; 2015; 10(7):e0131091. PubMed ID: 26222057
[TBL] [Abstract][Full Text] [Related]
18. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
Modest DP; Stintzing S; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Möhler M; Jung A; Kirchner T; Heinemann V
J Clin Oncol; 2015 Nov; 33(32):3718-26. PubMed ID: 26261259
[TBL] [Abstract][Full Text] [Related]
19. Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival.
Lee SH; Hayano K; Zhu AX; Sahani DV; Yoshida H
J Comput Assist Tomogr; 2015; 39(5):687-96. PubMed ID: 26222909
[TBL] [Abstract][Full Text] [Related]
20. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
